Palisade Bio (PALI) Income from Continuing Operations (2010 - 2026)
Palisade Bio (PALI) reported Income from Continuing Operations of 10749000.0 for Q1 2026, down 365.12% year-over-year from 4054339.64 in Q1 2025, and down 7.67% quarter-over-quarter from 9983000.0 in Q4 2025.
Palisade Bio (PALI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Income from Continuing Operations data on file, last reported at 10749000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 10749000.0, down 365.12% year-over-year; the trailing twelve-month figure through Mar 2026 was 26504000.0 (down 96.21% YoY), and the FY2025 annual result was 18066000.0, down 21.48% from the prior year.
- Income from Continuing Operations eased to 10749000.0 in Q1 2026 per PALI's latest filing, from 9983000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2311000.0 in Q1 2025 and troughed at 10749000.0 in Q1 2026.
- A 5-year average of 4265000.0 and a median of 3612000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations jumped 89.33% in 2022, then tumbled 365.12% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 3851000.0 in 2022, then grew by 18.0% to 3158000.0 in 2023, then retreated by 7.19% to 3385000.0 in 2024, then sank by 194.92% to 9983000.0 in 2025, then fell by 7.67% to 10749000.0 in 2026.
- Business Quant data shows PALI's Income from Continuing Operations at 10749000.0 in Q1 2026, 9983000.0 in Q4 2025, and 2927000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Palisade Bio | 391.02 Mn | 261.45 Mn | - | -10.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.98 Mn |
| Sep 30, 2025 | -2.93 Mn |
| Jun 30, 2025 | -2.85 Mn |
| Mar 31, 2025 | -2.31 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -4.21 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -3.61 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.42 Mn |
| Jun 30, 2022 | -3.58 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -3.04 Mn |
| Jun 30, 2021 | -33.51 Mn |